FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103991891> ?p ?o ?g. }

• W2103991891 endingPage "348" @default.
• W2103991891 startingPage "344" @default.
• W2103991891 abstract "<h3>OBJECTIVE</h3> To compare the efficacy, tolerability, and safety of three daily dosage regimens of oral piracetam in patients with progressive myoclonus epilepsy. <h3>METHODS</h3> Twenty patients (12 men, eight women), aged 17–43 years, with classical Unverricht-Lundborg disease were enrolled in a multicentre, randomised, double blind trial of crossover design in which the effects of daily doses of 9.6 g, 16.8 g, and 24 g piracetam, given in two divided doses, were compared with placebo. The crossover design was such that patients received placebo and two of the three dosage regimens of piracetam, each for two weeks, for a total treatment period of six weeks and thus without wash out between each treatment phase. The primary outcome measure was a sum score representing the adjusted total of the ratings of six components of a myoclonus rating scale in which stimulus sensitivity, motor impairment, functional disability, handwriting, and global assessments by investigators and patients were scored. Sequential clinical assessments were made by the same neurologist in the same environment at the same time of day. <h3>RESULTS</h3> Treatment with 24 g/day piracetam produced significant and clinically relevant improvement in the primary outcome measure of mean sum score (p=0.005) and in the means of its subtests of motor impairment (p=0.02), functional disability (p=0.003), and in global assessments by both investigator (p=0.002) and patient (p=0.01). Significant improvement in functional disability was also found with daily doses of 9.6 g and 16.8 g. The dose-effect relation was linear and significant. More patients showed clinically relevant improvement with the highest dosage and, in individual patients, increasing the dose improved response. Piracetam was well tolerated and adverse effects were few, mild, and transient. <h3>CONCLUSIONS</h3> This study provides further evidence that piracetam is an effective and safe medication in patients with Unverricht-Lundborg disease. In addition, it shows that a dose of 24 g is highly beneficial, more effective than lower doses and that a dose-effect relation exists. There is considerable variation in optimal individual dosage." @default.
• W2103991891 created "2016-06-24" @default.
• W2103991891 creator A5033203498 @default.
• W2103991891 creator A5042454755 @default.
• W2103991891 creator A5044891666 @default.
• W2103991891 creator A5054362845 @default.
• W2103991891 creator A5087642429 @default.
• W2103991891 date "1998-03-01" @default.
• W2103991891 modified "2023-10-12" @default.
• W2103991891 title "Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo" @default.
• W2103991891 cites W1584716486 @default.
• W2103991891 cites W1969009732 @default.
• W2103991891 cites W1971308705 @default.
• W2103991891 cites W1973421354 @default.
• W2103991891 cites W1977602647 @default.
• W2103991891 cites W1988173183 @default.
• W2103991891 cites W2021722828 @default.
• W2103991891 cites W2023435925 @default.
• W2103991891 cites W2033555101 @default.
• W2103991891 cites W2035760673 @default.
• W2103991891 cites W2052704919 @default.
• W2103991891 cites W2061151968 @default.
• W2103991891 cites W2064038251 @default.
• W2103991891 cites W2064597390 @default.
• W2103991891 cites W2065951306 @default.
• W2103991891 cites W2073220057 @default.
• W2103991891 cites W2084947252 @default.
• W2103991891 cites W2091571912 @default.
• W2103991891 cites W2091767236 @default.
• W2103991891 cites W2091980518 @default.
• W2103991891 cites W2116325277 @default.
• W2103991891 cites W2134750084 @default.
• W2103991891 cites W2161654769 @default.
• W2103991891 cites W2414186623 @default.
• W2103991891 cites W2436453903 @default.
• W2103991891 cites W2474421361 @default.
• W2103991891 doi "https://doi.org/10.1136/jnnp.64.3.344" @default.
• W2103991891 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2169975" @default.
• W2103991891 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9527146" @default.
• W2103991891 hasPublicationYear "1998" @default.
• W2103991891 type Work @default.
• W2103991891 sameAs 2103991891 @default.
• W2103991891 citedByCount "96" @default.
• W2103991891 countsByYear W21039918912012 @default.
• W2103991891 countsByYear W21039918912013 @default.
• W2103991891 countsByYear W21039918912014 @default.
• W2103991891 countsByYear W21039918912015 @default.
• W2103991891 countsByYear W21039918912016 @default.
• W2103991891 countsByYear W21039918912017 @default.
• W2103991891 countsByYear W21039918912018 @default.
• W2103991891 countsByYear W21039918912019 @default.
• W2103991891 countsByYear W21039918912020 @default.
• W2103991891 countsByYear W21039918912021 @default.
• W2103991891 countsByYear W21039918912022 @default.
• W2103991891 countsByYear W21039918912023 @default.
• W2103991891 crossrefType "journal-article" @default.
• W2103991891 hasAuthorship W2103991891A5033203498 @default.
• W2103991891 hasAuthorship W2103991891A5042454755 @default.
• W2103991891 hasAuthorship W2103991891A5044891666 @default.
• W2103991891 hasAuthorship W2103991891A5054362845 @default.
• W2103991891 hasAuthorship W2103991891A5087642429 @default.
• W2103991891 hasBestOaLocation W21039918911 @default.
• W2103991891 hasConcept C118552586 @default.
• W2103991891 hasConcept C126322002 @default.
• W2103991891 hasConcept C138496976 @default.
• W2103991891 hasConcept C142724271 @default.
• W2103991891 hasConcept C15744967 @default.
• W2103991891 hasConcept C162156334 @default.
• W2103991891 hasConcept C1862650 @default.
• W2103991891 hasConcept C187212893 @default.
• W2103991891 hasConcept C197934379 @default.
• W2103991891 hasConcept C204787440 @default.
• W2103991891 hasConcept C27081682 @default.
• W2103991891 hasConcept C2776538686 @default.
• W2103991891 hasConcept C2777496795 @default.
• W2103991891 hasConcept C2778186239 @default.
• W2103991891 hasConcept C2778375690 @default.
• W2103991891 hasConcept C42219234 @default.
• W2103991891 hasConcept C535046627 @default.
• W2103991891 hasConcept C71924100 @default.
• W2103991891 hasConcept C83849319 @default.
• W2103991891 hasConcept C87813604 @default.
• W2103991891 hasConceptScore W2103991891C118552586 @default.
• W2103991891 hasConceptScore W2103991891C126322002 @default.
• W2103991891 hasConceptScore W2103991891C138496976 @default.
• W2103991891 hasConceptScore W2103991891C142724271 @default.
• W2103991891 hasConceptScore W2103991891C15744967 @default.
• W2103991891 hasConceptScore W2103991891C162156334 @default.
• W2103991891 hasConceptScore W2103991891C1862650 @default.
• W2103991891 hasConceptScore W2103991891C187212893 @default.
• W2103991891 hasConceptScore W2103991891C197934379 @default.
• W2103991891 hasConceptScore W2103991891C204787440 @default.
• W2103991891 hasConceptScore W2103991891C27081682 @default.
• W2103991891 hasConceptScore W2103991891C2776538686 @default.
• W2103991891 hasConceptScore W2103991891C2777496795 @default.
• W2103991891 hasConceptScore W2103991891C2778186239 @default.
• W2103991891 hasConceptScore W2103991891C2778375690 @default.
• W2103991891 hasConceptScore W2103991891C42219234 @default.

• next